Securities Registration: Employee Benefit Plan (s-8)

Datum : 13/03/2018 @ 22h09
Quelle : Edgar (US Regulatory)
Name : Sunesis Pharmaceuticals, Inc. (SNSS)
Kurs : 2.14  0.0 (0.00%) @ 10h00
Sunesis Pharmaceuticals, Inc. share price Chart

Securities Registration: Employee Benefit Plan (s-8)

 

As filed with the Securities and Exchange Commission on March 13, 2018

Registration Statement No. 333-

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

REGISTRATION STATEMENT

Under

THE SECURITIES ACT OF 1933

 

Sunesis Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

94-3295878

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

395 Oyster Point Boulevard, Suite 400

South San Francisco, CA 94080

(Address of principal executive offices)

2011 Equity Incentive Plan

(Full title of the plan)

William P. Quinn

Chief Financial Officer, Senior Vice President, Finance and Corporate Development

395 Oyster Point Boulevard, Suite 400

South San Francisco, CA 94080

(650) 266-3500

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copy to:

Mehdi Khodadad

Cooley LLP

3175 Hanover Street

Palo Alto, California 94304-1130

Telephone: (650) 843-5000

Fax: (650) 849-7400

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  (Do not check if a smaller reporting company)

  

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

 

CALCULATION OF REGISTRATION FEE

Title of each Class of

Securities to be Registered

Amount

to be

Registered (1)

Proposed Maximum

Offering Price

Per Share(2)

Proposed Maximum

Aggregate

Offering Price(2)

Amount of

Registration Fee

2011 Equity Incentive Plan, Common Stock, par value $0.0001 per share

1,371,308 shares

$4.13

$5,663,502.04

$705.11

(1)

Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the registrant’s common stock that become issuable under the 2011 Equity Incentive Plan set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of the registrant’s common stock. In addition, pursuant to Rule 416(c) under the Securities Act, this Registration Statement also covers an indeterminate amount of interests to be offered or sold pursuant to the employee and non-employee benefit plans described herein.

(2)

Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the registrant’s common stock as reported on the Nasdaq Stock Market on March 12, 2018, in accordance with Rule 457(c) of the Securities Act.

 

 

 

 


 

EXPLANATORY NOTE

The Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements on Form S-8 of the Registrant relating to the same employee and non-employee benefit plans set forth herein are effective.

INCORPORATION BY REFERENCE OF CONTENTS OF

REGISTRATION STATEMENT ON FORM S-8

 

This Registration Statement on Form S-8 is filed by Sunesis Pharmaceuticals, Inc., a Delaware corporation (“Registrant”), relating to 1,371,308 shares of its Common Stock issuable to eligible employees, directors and consultants of Registrant and its affiliates under the 2011 Equity Incentive Plan (the “2011 Plan”). Registrant’s Forms S-8 Registration Statements filed with the U.S. Securities and Exchange Commission on June 6, 2011 (File No. 333-174732), March 14, 2012 (File No. 333-180101), March 13, 2013 (File No. 333-187234), May 7, 2014 (File No. 333-195781), March 12, 2015 (File No. 333-202696), March 14, 2016 (File No. 333-210183) and May 10, 2017 (File No. 333-217849) relating to the 2011 Plan are each incorporated by reference herein.

 

EXHIBITS

   

 

 

 

Incorporated By Reference

 

 

 

 

Exhibit

Number

 

Exhibit Description

 

Form

 

File No.

 

Exhibit

 

 

Filing Date

 

 

Filed

Herewith

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit

Number

 

Exhibit Description

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.1

 

Amended and Restated Certificate of Incorporation of the Registrant

 

 

10-K/A

 

 

000-51531

 

 

3.1

 

 

 

5/23/2007

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.2

 

Amended and Restated Bylaws of the Registrant

 

 

8-K

 

 

000-51531

 

 

3.2

 

 

 

12/11/2007

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.3

 

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant

 

 

S-8

 

 

333-160528

 

 

3.4

 

 

 

7/10/2009

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.4

 

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant

 

 

8-K

 

 

000-51531

 

 

3.1

 

 

 

2/14/2011

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.5

 

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant

 

 

8-K

 

 

000-51531

 

 

3.1

 

 

 

9/7/2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.6

 

Certificate of Designation of Series B Convertible Preferred Stock

 

 

8-K

 

 

000-51531

 

 

3.1

 

 

 

12/16/2015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.7

 

Certificate of Designation of Series C Convertible Preferred Stock

 

 

8-K

 

 

000-51531

 

 

3.1

 

 

 

10/19/2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.8

 

Certificate of Designation of Series D Convertible Preferred Stock

 

 

8-K

 

 

000-51531

 

 

3.1

 

 

 

10/26/2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.1

 

Reference is made to Exhibits 3.1 , 3.2 , 3.3 , 3.4 , 3.5 , 3.6 , 3.7 , and 3.8 above

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.2

 

Specimen Common Stock Certificate of the Registrant

 

 

10-K

 

 

000-51531

 

 

4.2

 

 

 

3/29/2011

 

 

 

 

 

 

5.1

 

 

Opinion of Cooley LLP.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

      X

 

 

 

23.1

 

 

Consent of Independent Registered Public Accounting Firm

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

      X

 

 

 

23.2

 

 

Consent of Cooley LLP (included in Exhibit 5.1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24.1

 

 

Power of Attorney (included on signature page)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

99.1

 

 

2011 Equity Incentive Plan, as amended

 

 

DEF 14A

 

 

000-51531

 

 

Appendix A

 

 

 

4/20/2017

 

 

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned thereunto duly authorized, in the City of South San Francisco, State of California, on this 13th day of March, 2018.

 

 

 

SUNESIS PHARMACEUTICALS, INC.

 

 

 

 

 

 

By:

/s/ WILLIAM P. QUINN

 

 

 

William P. Quinn

 

 

 

Chief Financial Officer, Senior Vice President, Finance and Corporate Development

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dayton Misfeldt and William P. Quinn and each of them acting individually, as his true and lawful attorney-in-fact and agent, with full power to act alone, with full powers of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorney-in-fact and agent, with full power to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

/S/  J AMES W. YOUNG, PH.D .

 

Chairman of the Board

 

March 13, 2018

James W. Young, Ph.D.

 

 

 

 

 

 

 

 

 

/S/ DAYTON MISFELDT

 

Interim Chief Executive Officer and Director (Principal Executive Officer)

 

March 13, 2018

Dayton Misfeldt

 

 

 

 

 

 

 

 

/S/ WILLIAM P. QUINN

 

Chief Financial Officer, Senior Vice President, Finance and Corporate Development (Principal Financial Officer and Principal Accounting Officer)

 

March 13, 2018

William P. Quinn

 

 

 

 

 

 

 

 

/S/ STEVE CARCHEDI

 

Director

 

March 13, 2018

Steve Carchedi

 

 

 

 

 

 

 

 

 

/S/ STEVEN B. KETCHUM, PH.D

 

Director

 

March 13, 2018

Steven B. Ketchum, Ph. D.

 

 

 

 

 

 

 

 

 

/S/ HOMER L. PEARCE, PH.D.

 

Director

 

March 13, 2018

Homer L. Pearce, Ph.D.

 

 

 

 

 

 

 

 

 

/S/  DAVID C. STUMP, M.D .

 

Director

 

March 13, 2018

David C. Stump, M.D.

 

 

 

 

 

 

 

 

 

/S/  H. Ward wolff

 

Director

 

March 13, 2018

H. Ward Wolff

 

 

 

 

 

 

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Historical Stock Chart

1 Jahr : Von Jun 2017 bis Jun 2018

Click Here for more Sunesis Pharmaceuticals, Inc. Charts.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)
Intraday Stock Chart

Heute : Montag 25 Juni 2018

Click Here for more Sunesis Pharmaceuticals, Inc. Charts.
Kürzlich von Ihnen besucht
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

Der Markt LS (Lang&Schwarz) wird als Realtime Indikation kostenlos angezeigt und bietet Ihnen außerbörsliche Realtime Aktienkurse in der Zeit von Mo-Fr 08:00 bis 23:00, Samstags 10:00 bis 13:00 und Sonntags an.
NYSE und AMEX Kurse sind um mindestens 20 Minuten zeitverzögert.
Alle weiteren Kurse sind um mindestens 15 Minuten zeitverzögert, sofern nicht anders angegeben.
P:41 V:de D:20180625 08:22:06